- Report
- October 2025
- 150 Pages
Global
From €3391EUR$3,850USD£2,981GBP
- Report
- September 2025
- 150 Pages
Global
From €3391EUR$3,850USD£2,981GBP
- Report
- June 2025
- 400 Pages
Global
From €4359EUR$4,949USD£3,831GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2456EUR$2,789USD£2,159GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2456EUR$2,789USD£2,159GBP
- Report
- August 2025
- 277 Pages
Global
From €3919EUR$4,450USD£3,445GBP
- Report
- June 2025
- 207 Pages
Global
From €4399EUR$4,995USD£3,867GBP
- Report
- September 2025
- 97 Pages
Global
From €3500EUR$4,257USD£3,184GBP
- Report
- September 2025
- 113 Pages
Global
From €3500EUR$4,257USD£3,184GBP
- Report
- July 2025
- 163 Pages
Global
From €13210EUR$14,999USD£11,612GBP
- Report
- November 2025
- 160 Pages
Global
From €2957EUR$3,358USD£2,599GBP
€3479EUR$3,950USD£3,058GBP
- Report
- November 2025
- 160 Pages
Global
From €2957EUR$3,358USD£2,599GBP
€3479EUR$3,950USD£3,058GBP
- Report
- October 2025
- 160 Pages
Global
From €2957EUR$3,358USD£2,599GBP
€3479EUR$3,950USD£3,058GBP
- Report
- October 2025
- 160 Pages
Global
From €2957EUR$3,358USD£2,599GBP
€3479EUR$3,950USD£3,058GBP
- Report
- October 2025
- 160 Pages
Global
From €2957EUR$3,358USD£2,599GBP
€3479EUR$3,950USD£3,058GBP
- Report
- October 2025
- 160 Pages
Global
From €2957EUR$3,358USD£2,599GBP
€3479EUR$3,950USD£3,058GBP
- Report
- October 2025
- 160 Pages
Global
From €2957EUR$3,358USD£2,599GBP
€3479EUR$3,950USD£3,058GBP
- Report
- October 2025
- 160 Pages
Global
From €2957EUR$3,358USD£2,599GBP
€3479EUR$3,950USD£3,058GBP
- Report
- October 2025
- 160 Pages
Global
From €2957EUR$3,358USD£2,599GBP
€3479EUR$3,950USD£3,058GBP
- Report
- October 2025
- 160 Pages
Global
From €2957EUR$3,358USD£2,599GBP
€3479EUR$3,950USD£3,058GBP

Bispecific antibodies are a type of biotechnology that are used to target two different antigens simultaneously. They are engineered to bind to two different epitopes on the same or different antigens, allowing them to act as a bridge between two different cells or molecules. Bispecific antibodies have been used in a variety of therapeutic applications, including cancer immunotherapy, autoimmune diseases, and infectious diseases.
Bispecific antibodies have the potential to improve the efficacy of existing treatments and to develop new treatments for diseases that have not yet been addressed. They can also be used to target multiple antigens at once, allowing for more efficient and effective treatments.
The bispecific antibodies market is expected to grow significantly in the coming years due to the increasing demand for targeted therapies and the development of new technologies. Companies in the market include AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Genentech, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more